Clinical trials: Infliximab
Psoriasis
Assessment of Long-Term Infliximab for Psoriasis (P05319)
This is a prospective Phase 4, open-label, non-randomized, observational, multi-center study of infliximab in participants with plaque-type psoriasis to assess the clinical response in real-world practice of long-term maintenance…
- Trial name
- REALITY (NCT00779675)
- Testing
- Infliximab
- Volunteers
- 660 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis, Juvenile
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Juvenile Rheumatoid Arthritis
The purpose of this study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with Juvenile Rheumatoid Arthritis (JRA).
- Trial name
- NCT00036374
- Testing
- Infliximab
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Centocor, Inc.
Ulcerative Colitis
A Study to Evaluate the Effectiveness and Safety of Infliximab in Chinese Patients With Active Ulcerative Colitis
The purpose of this study is to evaluate the effectiveness and safety of infliximab in Chinese patients with active ulcerative colitis (swelling and ulceration of large intestine and rectum).
- Trial name
- NCT01551290
- Testing
- Infliximab
- Where
- 7 sites in China
- Volunteers
- 99 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Sarcoidosis
A Study of Infliximab in Patients With Sarcoidosis
The purpose of this study is to evaluate the safety and effectiveness of infliximab (Remicade) in patients with Chronic Sarcoidosis.
- Trial name
- NCT00073437
- Testing
- Infliximab
- Volunteers
- 139 people
- Sponsor
- Centocor, Inc.
Crohn's Disease
Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)
The purpose of this study is to assess the efficacy, safety and pharmacokinetics after administration of 10mg/kg TA-650 every 8 weeks to patients with Crohn's disease showing an insufficient response to previous treatment with 5…
- Trial name
- NCT00805766
- Testing
- TA-650
- Where
- 4 sites in Japan
- Volunteers
- 39 people
- Sponsor
- Tanabe Pharma Corporation
Rheumatoid Arthritis
Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice
To compare retention rates of adalimumab, etanercept and infliximab as first-line biotherapy in rheumatoid arthritis (RA), to determine causes of discontinuation, retention-associated factors, and retention rates of possible…
- Trial name
- MAINTAIN (NCT01692899)
- Volunteers
- 780 people
- Sponsor
- Pfizer
Crohn's Disease
CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)
This is Phase 3, Randomized, Placebo-controlled study to demonstrate superiority of CT-P13 SC over Placebo SC in Patients With Moderately to Severely Active Crohn's Disease
- Trial name
- NCT03945019
- Testing
- CT-P13 SC (Infliximab)
- Where
- 29 sites in United States, Belarus and 24 more
- Volunteers
- 396 people
- Sponsor
- Celltrion
Psoriasis
Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315)
Participants from an ongoing observational study (P05319) who have a limited (adequate but less than optimal) response to infliximab will be randomized to either increase the frequency of infliximab infusions from every 8 weeks…
- Trial name
- DOSE (NCT00833053)
- Testing
- Infliximab, Infliximab and methotrexate
- Volunteers
- 39 people
- Sponsor
- Merck Sharp & Dohme LLC
Crohn´s Disease
Real-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s Disease
Hyrimoz™ was developed as a biosimilar to HumiraTM (INN: adalimumab) and Zessly™ was developed as a biosimilar to RemicadeTM (INN: infliximab).
- Trial name
- GIANT (NCT03890445)
- Where
- 18 sites in Austria, Germany and 3 more
- Volunteers
- 63 people
- Sponsor
- Sandoz
Psoriasis
Five-Year Observation of Remicade Treatment for Plaque Psoriasis in Austria (Study P04900)
Prospective, open-label-, 1-arm, multicenter observational study to determine the dose and interval of Infliximab infusions for subjects with plaque psoriasis.
- Trial name
- NCT00725452
- Testing
- Infliximab
- Volunteers
- 26 people
- Sponsor
- Merck Sharp & Dohme LLC
Crohn's Disease
The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy
This is a pilot study to estimate the efficacy of infliximab in inducing and maintaining healing of lesions in the mucosa of subjects with Crohn's disease involving their small bowel.
- Trial name
- ICE (NCT01181765)
- Testing
- Infliximab 5 mg/kg body weight infused over 2 hours
- Where
- 2 sites in Canada
- Volunteers
- 1 people
- Sponsor
- Janssen Inc.
Ankylosing Spondylitis
An Extension Study to Demonstrate the Equivalence of Long-Term Efficacy and Safety of CT-P13 in Patients With Ankylosing Spondylitis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 1.1
This open-label, single-arm, multicenter, multiple single-dose intravenous (IV) infusion, efficacy, and safety extension study of the Phase 1 Study CT-P13 1.1 is designed to assess the long-term efficacy and safety of multiple…
- Trial name
- NCT01571206
- Testing
- Infliximab
- Where
- South Korea
- Volunteers
- 174 people
- Sponsor
- Celltrion
Psoriasis
A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612)
Subjects with moderate-to-severe chronic psoriasis not responding to standard or biologic therapy will be eligible to enroll in this study.
- Trial name
- ESAQUALITY (NCT00687401)
- Testing
- Infliximab
- Volunteers
- 215 people
- Sponsor
- Merck Sharp & Dohme LLC
Arthritis, Rheumatoid
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
The purpose of this study is to compare the proportion of patients with an infusion reaction in Rheumatoid arthritis (RA) patients treated with Golimumab Intravenous (IV) or Infliximab.
- Trial name
- AWARE (NCT02728934)
- Testing
- Golimumab Intravenous (IV), Infliximab, Biosimilar Infliximab
- Where
- 85 sites in United States
- Volunteers
- 1,279 people
- Sponsor
- Janssen Scientific Affairs, LLC
Pediatric Ulcerative Colitis
Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis
The purpose of this study is to evaluate the the efficacy of TA-650 using Clinical activity index (CAI) score and other evaluation indicators in pediatric patients with moderate to severe ulcerative colitis after TA-650…
- Trial name
- NCT01585155
- Testing
- TA-650
- Where
- 7 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Tanabe Pharma Corporation
Giant Cell Arteritis
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis
The purpose of this study is to evaluate the safety and efficacy (effectiveness) of Infliximab (Remicade) in patients with Giant Cell Arteritis.
- Trial name
- NCT00076726
- Testing
- Infliximab
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Centocor, Inc.
Rheumatoid Arthritis
Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)
This Phase 3, randomized, open-label, multicenter study in rheumatoid arthritis (RA) patients with low disease activity (Disease Activity Score 28 [DAS28] >2.8 and <3.5) is being conducted to evaluate induction of remission by…
- Trial name
- NCT00521924
- Testing
- infliximab, DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89.
- Volunteers
- 8 people
- Sponsor
- Merck Sharp & Dohme LLC
Arthritis, Psoriatic
A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic Arthritis
The purpose of this study is to determine if Infliximab is safe and effective in the treatment of psoriatic arthritis. Infliximab (Remicade) targets specific proteins in the body's immune system to help control the development of…
- Trial name
- NCT00051623
- Testing
- Infliximab
- Volunteers
- 70 people
- Sponsor
- Centocor, Inc.